BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24196395)

  • 1. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
    Bard J; Wall MD; Lazari O; Arjomand J; Munoz-Sanjuan I
    J Biomol Screen; 2014 Feb; 19(2):191-204. PubMed ID: 24196395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
    Lu B; Palacino J
    FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
    Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
    J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivation of Huntington's disease-affected human embryonic stem cell lines.
    Bradley CK; Scott HA; Chami O; Peura TT; Dumevska B; Schmidt U; Stojanov T
    Stem Cells Dev; 2011 Mar; 20(3):495-502. PubMed ID: 20649476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of human stem cells in Huntington disease modeling and translational research.
    Golas MM; Sander B
    Exp Neurol; 2016 Apr; 278():76-90. PubMed ID: 26826449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
    Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
    J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calretinin interacts with huntingtin and reduces mutant huntingtin-caused cytotoxicity.
    Dong G; Gross K; Qiao F; Ferguson J; Callegari EA; Rezvani K; Zhang D; Gloeckner CJ; Ueffing M; Wang H
    J Neurochem; 2012 Nov; 123(3):437-46. PubMed ID: 22891683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic mechanisms in Huntington's disease.
    Jones L; Hughes A
    Int Rev Neurobiol; 2011; 98():373-418. PubMed ID: 21907095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
    Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
    Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant palmitoylation in Huntington disease.
    Sanders SS; Hayden MR
    Biochem Soc Trans; 2015 Apr; 43(2):205-10. PubMed ID: 25849918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington disease and the huntingtin protein.
    Zheng Z; Diamond MI
    Prog Mol Biol Transl Sci; 2012; 107():189-214. PubMed ID: 22482451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse models of Huntington's disease.
    Menalled LB; Chesselet MF
    Trends Pharmacol Sci; 2002 Jan; 23(1):32-9. PubMed ID: 11804649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.